
Murat Cokol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1956891/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Scientific Reports, 2021, 11, 11861.	3.3	10
2	Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111340.	5.0	18
3	Antibiotic susceptibility signatures identify potential antimicrobial targets in the Acinetobacter baumannii cell envelope. Nature Communications, 2020, 11, 4522.	12.8	62
4	Guided screen for synergistic three-drug combinations. PLoS ONE, 2020, 15, e0235929.	2.5	7
5	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		0
6	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		0
7	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		0
8	Guided screen for synergistic three-drug combinations. , 2020, 15, e0235929.		0
9	Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion. Scientific Reports, 2019, 9, 11876.	3.3	24
10	Prediction of ultra-high-order antibiotic combinations based on pairwise interactions. PLoS Computational Biology, 2019, 15, e1006774.	3.2	49
11	Miniaturized Checkerboard Assays to Measure Antibiotic Interactions. Methods in Molecular Biology, 2019, 1939, 3-9.	0.9	10
12	Characterizing ABC-Transporter Substrate-Likeness Using a Clean-Slate Genetic Background. Frontiers in Pharmacology, 2019, 10, 448.	3.5	1
13	A Novel Composition of Endogenous Metabolic Modulators, AXA4010, Impacts Adhesion, Inflammation and RBC Membrane Deformability in Preclinical Models of Sickle Cell Disease. Blood, 2019, 134, 978-978.	1.4	1
14	Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment. PLoS Computational Biology, 2018, 14, e1006677.	3.2	31
15	Modeling the impact of drug interactions on therapeutic selectivity. Nature Communications, 2018, 9, 3452.	12.8	18
16	Diagonal Method to Measure Synergy Among Any Number of Drugs. Journal of Visualized Experiments, 2018, , .	0.3	25
17	Prediction of synergistic drug combinations. Current Opinion in Systems Biology, 2017, 4, 24-28.	2.6	26
18	Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure. Journal of Medicinal Chemistry, 2017, 60, 3902-3912.	6.4	45

MURAT COKOL

#	Article	IF	CITATIONS
19	A Parallel Adder Coordinates Mycobacterial Cell-Cycle Progression and Cell-Size Homeostasis in the Context of Asymmetric Growth and Organization. Current Biology, 2017, 27, 3367-3374.e7.	3.9	62
20	Efficient measurement and factorization of high-order drug interactions in <i>Mycobacterium tuberculosis</i> . Science Advances, 2017, 3, e1701881.	10.3	107
21	Synthesis and characterization of amino acid-functionalized calcium phosphate nanoparticles for siRNA delivery. Colloids and Surfaces B: Biointerfaces, 2017, 158, 175-181.	5.0	30
22	Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 6843-6855.	2.0	30
23	Chemogenomics and orthologyâ€based design of antibiotic combination therapies. Molecular Systems Biology, 2016, 12, 872.	7.2	96
24	Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discovery Today, 2016, 21, 225-238.	6.4	162
25	Temporal and intrinsic factors of rifampicin tolerance in mycobacteria. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8302-8307.	7.1	44
26	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery, 2015, 5, 1210-1223.	9.4	575
27	Strength of Selection Pressure Is an Important Parameter Contributing to the Complexity of Antibiotic Resistance Evolution. Molecular Biology and Evolution, 2014, 31, 2387-2401.	8.9	222
28	Large-Scale Identification and Analysis of Suppressive Drug Interactions. Chemistry and Biology, 2014, 21, 541-551.	6.0	27
29	A drug similarity network for understanding drug mechanism of action. Journal of Bioinformatics and Computational Biology, 2014, 12, 1441007.	0.8	1
30	Target-Independent Prediction of Drug Synergies Using Only Drug Lipophilicity. Journal of Chemical Information and Modeling, 2014, 54, 2286-2293.	5.4	30
31	Oxidative Stress Is a Mediator for Increased Lipid Accumulation in a Newly Isolated Dunaliella salina Strain. PLoS ONE, 2014, 9, e91957.	2.5	247
32	Drugs and their Interactions. Current Drug Discovery Technologies, 2013, 10, 106-113.	1.2	14
33	Systematic exploration of synergistic drug pairs. Molecular Systems Biology, 2011, 7, 544.	7.2	284
34	The Genetic Landscape of a Cell. Science, 2010, 327, 425-431.	12.6	1,937
35	Visualizing evolution and impact of biomedical fields. Journal of Biomedical Informatics, 2008, 41, 1050-1052.	4.3	17
36	A Protein Domain-Based Interactome Network for C. elegans Early Embryogenesis. Cell, 2008, 134, 534-545.	28.9	196

MURAT COKOL

#	Article	IF	CITATIONS
37	How many scientific papers should be retracted?. EMBO Reports, 2007, 8, 422-423.	4.5	63
38	Response by Cokol <i>et al</i> . EMBO Reports, 2007, 8, 793-793.	4.5	0
39	Emergent behavior of growing knowledge about molecular interactions. Nature Biotechnology, 2005, 23, 1243-1247.	17.5	51
40	Finding nuclear localization signals. EMBO Reports, 2000, 1, 411-415.	4.5	626